Redmile Group Reorganizes Fate Therapeutics Holdings via Internal Subsidiary Transfer

This Amendment No. 10 to Schedule 13D, filed on April 22, 2026, details an internal reorganization of assets held by Redmile Group, LLC and its affiliates regarding Fate Therapeutics, Inc. (FATE). On April 20, 2026, RedCo II Master Fund, L.P. contributed all of its securities in the Issuer pro rata and in kind to its two wholly-owned subsidiaries, including RedCo II Offshore SPV LLC. These securities included 8,977,624 shares of common stock, pre-funded warrants, and preferred stock. Consequently, RedCo II Master Fund, L.P. ceased to be a beneficial owner and will be dissolved, while RedCo II Offshore SPV LLC became a beneficial owner of approximately 8.5% of the common stock. Despite this internal shift, the aggregate beneficial ownership managed by Redmile Group, LLC and its managing member, Jeremy C. Green, remains unchanged at 18,229,078 shares, representing a 14.9% stake. This total reflects common shares held across various Redmile funds, vested options, and shares issuable upon conversion of preferred stock and warrants, subject to beneficial ownership blockers.